Light therapy plus immunotherapy: new hope for Tough-to-Treat mesothelioma
NCT ID NCT04400539
Summary
This small pilot study is testing whether a two-part treatment is safe and feasible for people with advanced, inoperable mesothelioma that has worsened after standard chemotherapy. First, doctors use a special light therapy during a minimally invasive chest surgery to target cancer cells. Then, patients receive an immunotherapy drug called nivolumab to help their immune system fight remaining cancer. The main goal is to see if patients can complete both treatments without severe side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institut Coeur-Poumon, CHU
RECRUITINGLille, 59037, France
Conditions
Explore the condition pages connected to this study.